Lipodystrophic syndromes associated with mutations in LMNA, encoding A-type lamins, and with HIV antiretroviral treatments share several clinical characteristics. Nuclear alterations and prelamin A accumulation have been reported in fibroblasts from patients with LMNA mutations and adipocytes exposed to protease inhibitors (PI). As genetically altered lamin A maturation also results in premature ageing syndromes with lipodystrophy, we studied prelamin A expression and senescence markers in cultured human fibroblasts bearing six different LMNA mutations or treated with PIs. As compared to control cells, fibroblasts with LMNA mutations or treated with PIs had nuclear shape abnormalities and reduced proliferative activity that worsened with increasing cellular passages. They exhibited prelamin A accumulation, increased oxidative stress, decreased expression of mitochondrial respiratory chain proteins and premature cellular senescence. Inhibition of prelamin A farnesylation prevented cellular senescence and oxidative stress. Adipose tissue samples from patients with LMNA mutations or treated with PIs also showed retention of prelamin A, overexpression of the cell cycle checkpoint inhibitor p16 and altered mitochondrial markers. Thus, both LMNA mutations and PI treatment result in accumulation of farnesylated prelamin A and oxidative stress that trigger premature cellular senescence. These alterations could participate in the pathophysiology of lipodystrophic syndromes and lead to premature ageing complications.
Mutations in the LMNA gene encoding A-type lamins cause inherited laminopathies, including lipodystrophies with metabolic alterations and early cardiovascular disease, and premature ageing syndromes (reviewed by Mattout et al 1 ) . LMNA-linked lipodystrophies and progeroid syndromes form a clinical continuum of related phenotypes. [2] [3] [4] [5] [6] [7] [8] Otherwise, HIV-infected patients receiving antiretroviral therapy frequently develop a lipodystrophy syndrome associated with a high risk of metabolic and cardiovascular complications. 9 These patients also face a growing number of other agerelated comorbidities, such as neurodegeneration, osteopenia and malignancies. 10 A-type lamins are nuclear proteins required for the structural and functional integrity of the nucleus. Lamin A is translated as a protein precursor that undergoes several maturation steps, including the addition of a C-terminal farnesyl residue, which is subsequently removed by proteolytic cleavage (reviewed by Mattout et al 1 ). Defective physiological maturation of prelamin A is the main pathophysiological mechanism underlying several premature ageing syndromes, including the Hutchinson-Gilford progeria syndrome (HGPS) (reviewed by Young et al 11 ) . Several studies have convincingly demonstrated that the retention of the farnesylated residue confers toxic properties to the partially processed prelamin A. [11] [12] [13] Both cellular abnormalities [14] [15] [16] [17] and premature ageing phenotype in mice 18 are significantly improved by using drugs that inhibit prelamin A farnesylation.
The HIV antiretroviral protease inhibitors (PIs) indinavir and nelfinavir impede prelamin A maturation in cultured adipocytes, 19, 20 and induce nuclear alterations similar to those observed in LMNA-mutated fibroblasts. 19, 21 Interestingly, these alterations occur in fibroblasts from patients with LMNA-linked lipodystrophies and premature ageing syndromes (reviewed by Mattout et al 1 ). These data let us to suspect that lipodystrophic syndromes related to LMNA mutations or PI treatment could be considered as, respectively, genetic and acquired laminopathies, and could share common pathophysiological mechanisms, including premature cellular senescence.
Senescence, defined as a series of cellular changes associated with ageing, [22] [23] [24] results from a signal transduction program leading to irreversible arrest of cell growth and a distinct set of changes in the cellular phenotype. Cellular senescence can be induced prematurely by various agents and stimuli, including oxidative stress. 25 The free-radical theory of ageing postulates that the production of intracellular reactive oxygen species (ROS) is the major determinant of lifespan. 26 Abundant evidence also implicates mitochondrial changes in the ageing process. 26, 27 Human fibroblasts offer a good model for studying the cellular ageing process in vitro. 28 In primary culture, fibroblasts proliferate readily but have a limited proliferative potential, ultimately leading to a state of replicative senescence. Senescent fibroblasts show irreversible growth arrest, but remain viable for extended periods of time. They are characterized by their distinct morphology, expression of senescence-associated b-galactosidase (SA-b-galactosidase) activity 29 and upregulation of cell cycle checkpoint inhibitors. 25, 30 In this study, we used primary cultures of skin fibroblasts originating from lipodystrophic patients bearing LMNA mutations, or control fibroblasts treated with indinavir or nelfinavir in vitro and patients' adipose tissue biopsies. We showed that all conditions were associated with defective prelamin A processing and triggered cellular premature senescence, which was prevented by inhibition of prelamin A farnesylation. Mitochondrial alterations and oxidative damage resulting from the toxicity of partially processed prelamin A could, at least in part, underlie the premature senescence phenotype.
Results
Human fibroblasts with LMNA mutations or treated with PIs have similar nuclear shape abnormalities and overexpress prelamin A. Fibroblasts with LMNA mutations (heterozygous mutations D47Y, L92F, L387V, R399H, L421P and R482W) originated from patients with insulin resistance and/or lipodystrophy, as described in Materials and methods. Nuclear shape abnormalities increased during successive passages, affecting up to 40-60% of total nuclei in fibroblasts with LMNA mutations or treated with PIs (Figure 1a and b). The nuclear abnormalities were similar in the different conditions, except in D47Y LMNA-mutated cells, originating from the only patient exhibiting clinical signs of accelerated ageing, in which the nuclei were more markedly lobulated (Figure 1a ). Lamin B staining was reduced in nuclear blebs, affecting 20-40% of abnormally shaped nuclei in both fibroblasts with LMNA mutations or treated with PIs ( Figure 1a) .
While prelamin A expression, assessed with a prelamin Aspecific antibody (SC-6214) was barely detected in control fibroblast lysates, it was markedly increased in fibroblasts from the six patients with LMNA mutations and in cells treated with indinavir or nelfinavir (Figure 2a ), but not with the nonpeptidomimetic PI atazanavir (data not shown). Prelamin A was also detected as an additional band with retarded electrophoretic mobility in both cells with LMNA mutations or treated with PIs by probing the Western blot with an anti-lamin antibody that recognizes both lamin A/C and prelamin A (SC-7292, 31 ) (Figure 2a ). Immunofluorescence studies indicated that prelamin A accumulated at the nuclear rim, predominantly in the nuclear herniations (Figure 2b and data not shown). Prelamin A was also observed in lysates of subcutaneous adipose tissue from two patients bearing LMNA mutations and from four HIV-infected patients under treatment including indinavir or nelfinavir, but not in adipose tissue lysates from healthy subjects (Figure 2c ). LMNA mutations and PI treatment did not alter the amount of lamin A/C, both in fibroblasts and adipose tissue (Figure 2a and c) .
LMNA mutations and PI treatment reduce the proliferative and replicative capacity of cultured fibroblasts. The population doubling level (PDL) of untreated control fibroblasts remained stable up to passage 16, at 2.6970.05 (Figure 3a) . In contrast, the proliferation rate of fibroblasts with LMNA mutations or treated with PIs decreased rapidly. Half-maximal inhibition of PDL and arrest of cell division (PDLo0.5) were observed between passages 10 and 14 or between passages 5 and 10 in fibroblasts with LMNA mutations or treated with PIs, respectively, apart from D47Y-mutated cells, which stopped proliferating at passage 7. Consistent with these results, the cumulative PDL (CPDL) was significantly and similarly reduced, by 50-60%, in fibroblasts with LMNA mutations or treated with PIs, except for those bearing the D47Y mutation (80% decrease) (Figure 3b) .
LMNA mutations and PI treatment also induced a striking decrease in fibroblasts' replicative capacity, measured in terms of bromodeoxyuridine (BrdU) incorporation in halfconfluent cells (Figure 4a ). Interestingly, most of these BrdUnegative fibroblasts were enlarged and flattened, with abnormally shaped nuclei-morphologic changes typically associated with senescence ( Figure 4a ). Positive and negative controls of BrdU incorporation were obtained by treating fibroblasts with activators (insulin 10 À6 M and fetal bovine serum (FBS) 20%, 24 h) or with an inhibitor (etoposide 20 mM, 12 h) of proliferation, thus confirming the sensitivity of the replication assay (Figure 4a ).
Apoptotic cells identified by flow cytometry represented less than 4% of total cells in fibroblasts with LMNA mutations or treated with PIs and in control fibroblasts (Figure 4b ). Moreover, Western blots from whole-cell lysates showed no evidence of caspase 3-mediated PARP proteolysis (Figure 4b ), a strong indicator of apoptosis. At late passages (passage 16), PARP lysis was slightly increased in PI-treated cells and in some, but not all, patients' fibroblasts (data not shown). with PIs (data not shown). In contrast, SA-b-galactosidase activity, assessed at pH 6, was absent in control cells up to passage 14, but present, even at early passages, in fibroblasts with LMNA mutations or treated with PIs ( Figure 5b and data not shown). X-gal-stained fibroblasts with LMNA mutations were present at passage 4 and their number increased moderately thereafter (Figure 5b ). Indinavir and nelfinavir both rapidly induced a 40-to 60-fold increase in the number of blue X-gal-stained cells at pH 6, accounting for 35-65% of total cells at passage 4 ( Figure 5b) . No SA-b-galactosidase activity was observed in control fibroblasts studied until passage 14 ( Figure 5b and data not shown). Microscopic examination showed that the fibroblasts with LMNA mutations or treated with PIs that were stained with X-gal at pH 6 also harbored the morphologic alterations that characterize senescent cells, and that most of them had an altered nuclear structure (Figure 5b ).
Fibroblasts with LMNA mutations or treated with PIs and patients' adipose tissue show mitochondrial alterations. As mitochondria are key actors in cellular ageing, 26, 27 we examined whether the expression of respiratory chain proteins was altered by LMNA mutations or PI treatment. As shown in Figure 6a , expression of the mitochondrial DNA-encoded subunit II of the cytochrome oxidase complex IV (COX2), but not of the nuclear DNAencoded subunit IV of the same complex (COX4), was strikingly decreased in fibroblasts bearing LMNA mutations or treated with PIs, as compared with control cells. In adipose tissue samples from patients with LMNA mutations or under PI treatment, COX2 expression was lower than in control samples (Figure 6b ). COX4 expression was not modified in fat samples from lipodystrophic HIV-infected patients, although it was decreased in parallel with COX2 in adipose tissue from patients with LMNA mutations. Consistent with PI-induced mitochondrial dysfunction, we observed that longterm treatment of cultured fibroblasts (passages 9
Production of ROS is increased in fibroblasts with LMNA mutations or treated with PIs. ROS are strong inducers of replicative senescence and are produced in excess by defective mitochondria. [23] [24] [25] [26] ROS production was evaluated indirectly by measuring the oxidation status of the permeant derivatives CM-H 2 DCFDA and the reduction of nitroblue tetrazolium (NBT). As depicted in Figure 7a , dichlorofluorescein oxidation was increased two-to fivefold in fibroblasts with LMNA mutations at passages 6-8, as compared to control cells. PI-treated fibroblasts also had a higher redox status than control fibroblasts, as shown by a twofold increase in CM-H 2 DCFDA oxidation at passages 3-4 ( Figure 7a ). The PI effects were maximal at passage 10 (four-to fivefold increase over control). ROS hyperproduction in PI-treated fibroblasts was confirmed by measuring NBT reduction, which was significantly increased at all passages tested (Figure 7a ).
Microscopic examination (Figure 7b ) confirmed the increased production of ROS in fibroblasts with LMNA mutations and treated with PIs, as compared to control fibroblasts. CM-H 2 DCFDA fluorescence was enhanced in the typically senescent fibroblasts whose cytoplasm was enlarged and flattened. Moreover, mitochondria staining of senescent fibroblasts, assessed by MitoTracker Red 580 probe (MTR) red fluorescence, colocalized with CM-H 2 DCFDA fluorescence (Figure 7b ), suggesting that mitochondria were the main source of ROS.
Inhibition of farnesylation prevents excessive ROS production and cellular senescence in fibroblasts with LMNA mutations or treated with PIs. To test whether prelamin A farnesylation could account for oxidative stress and premature senescence, we incubated control fibroblasts and those with LMNA mutations or treated with PIs (passages 4-6) with the highly potent and selective inhibitor of farnesyl transferases (FTI)-277 32 or the isoprenoid synthesis inhibitor mevinolin (data not shown). We verified the efficiency of the drugs by studying HDJ-2, a farnesylated CaaX protein whose electrophoretic mobility is retarded when farnesylation is inhibited. 32 We indeed observed that 50-60% of HDJ-2 was unfarnesylated in lysates from cells treated with FTI-277 or mevilonin (Figure 8a and data not shown). These data strongly suggest that increased oxidative stress and premature senescence in both fibroblasts with LMNA mutations or treated with PIs may result, at least in part, from the toxicity of unproperly processed farnesylated prelamin A.
Discussion
Lipodystrophic syndromes associated with LMNA mutations and HIV antiretroviral treatment share major clinical and biological features. Both disorders mainly affect peripheral fat, whereas central adipose tissue is frequently hypertrophic. Metabolic features include hypertriglyceridemia, insulin resistance, altered glucose tolerance, early cardiovascular complications and hepatic disorders.
9,33 LMNA-linked lipodystrophy syndromes and premature ageing also share several clinical similarities, [2] [3] [4] [5] and HIV-infected patients on Figure 7 Increased production of ROS in fibroblasts with LMNA mutations or treated with PIs. (a) ROS production was assessed in terms of the oxidation of CM-H 2 DCFDA derivatives (at 520 nm) and normalized to the DNA content. CM-H 2 DCFDA/DNA was assessed at passages 6-8 in fibroblasts with LMNA mutations and at each indicated passage for PI-treated fibroblasts. DMSO treatment (0.01%) did not alter ROS production in control fibroblasts. In PI-treated fibroblasts, ROS production was also measured in terms of the reduction of NBT. Experiments were performed in triplicate. Results are mean7S.E.M. *Po0.05. (b) Cells were stained using the CM-H 2 DCFDA derivatives (ROS-induced oxidation results in green labeling) and the fluorescent mitochondrial marker MitoTracker Red MTR (red labeling) and were examined by fluorescence microscopy. The predominant perinuclear mitochondrial staining of control cells was lost in fibroblasts treated with PIs or bearing LMNA mutations. Merged images show the colocalization of mitochondria and ROS production. Scale bars represent 20 mm antiretrovirals have a significantly increased risk of ageingassociated comorbidities. 10 By using cultured fibroblasts, we observed further similarities between alterations associated with LMNA mutations or HIV antiretroviral treatment. Indeed, nuclear shape and lamina composition were similarly altered and the prevalence of dysmorphic nuclei during cell passages increased similarly, pointing to the existence of common underlying pathophysiological mechanisms.
Our study shows that prelamin A accumulation, predominantly at the nuclear rim, is a common feature of fibroblasts with LMNA mutations or treated with PIs. The interaction between A-and B-type lamins is altered in both situations, pointing to a defective setup of the lamina meshwork, that has been already described in HGPS cells. 4, 5, 8, 11 The increased amount of prelamin A in adipose tissue samples from lipodystrophic patients bearing LMNA mutations or treated with PIs indicates that prelamin A accumulation is occuring in vivo. Moreover, lipodystrophy itself could result from defective prelamin A processing, as sterol-regulatory element-binding protein-1, which contributes to adipogenesis, is sequestrated at the nuclear rim in cells with other LMNA mutations 7 and in preadipocytes chronically treated with PIs, 21 thereby impairing adipocyte differentiation. However, the role of lamin A in adipocyte differentiation is unclear. 20, 34 We obtained several lines of evidence suggesting that prelamin A accumulation is associated with signs of premature senescence both in fibroblasts and adipose tissue. First, proliferative and replicative activities were similarly decreased in fibroblasts with LMNA mutations or treated with PIs, an effect independent of apoptosis. Second, the cyclindependent kinase inhibitors p16
INK4a and p21 WAFÀ1 , which mediate cell cycle arrest through retinoblastoma protein phosphorylation, 30 were overexpressed. Upregulation of p21 and other p53 target genes has previously been observed in tissues from Zmpste24-knockout mice. 35 Third, typical morphologic features of senescent cells and specific SA-bgalactosidase activity were observed in fibroblasts with LMNA mutations or treated with PIs, but not in control cells.
The pathophysiology of laminopathies with premature ageing is thought to result from the retention of unprocessed farnesylated prelamin A. Prelamin A maturation is a complex process, involving the addition of a farnesyl group to the Cterminal tail, with secondary enzymatic release by the zinc metalloprotease Zmpste24 (reviewed by Mattout et al 1 ). Due to the efficiency of the enzymatic machinery, prelamin A is virtually undetectable in wild-type or untreated cells. LMNA mutations leading to a deleted Zmpste24 cleavage site and ZMPSTE24 mutations, both by directly blocking proteolysis of farnesylated prelamin A, result in severe premature ageing phenotypes in humans 4,5,31 and mice. 35, 36 Interestingly, prelamin A accumulation has also been reported in fibroblasts from patients with familial partial lipodystrophy of the Dunnigan type (LMNA mutation R482L) and atypical progeroid syndromes (LMNA mutations R527H and S143F), but not from a patient with muscular dystrophy due to the R401C substitution. 7 Indeed, phenotypes of laminopathies with lipodystrophy, insulin resistance and/or premature ageing are clinically related. [2] [3] [4] [5] The defective prelamin A processing associated with different heterozygous substitutions in the protein could result from an altered recognition of the mutated prelamin A by the Zmpste24 protease. 7 The present data, observed with other LMNA mutations responsible for insulin resistance and/or lipodystrophy (D47Y, L92F, L387V, R399H, L421P and R482W), are in agreement with this hypothesis. In fibroblasts treated with the PIs indinavir and nelfinavir, we propose that impaired prelamin A proteolytic maturation could be due to an inhibitory effect of these drugs on the activity of the metalloprotease Zmpste24. Thus, farnesylated prelamin A accumulation is probably the initial event, shared by cells with LMNA mutations or treated with indinavir and nelfinavir, that triggers premature ageing. Interestingly, treating the cells with atazanavir, a nonpeptidomimetic PI, did not induce prelamin A accumulation, thus reinforcing the concept that structural determinants in the PI molecules might be involved in Zmpste24 inhibition.
FTI prevent cellular senescence in fibroblasts from patients with HGPS, strongly arguing for the cellular toxicity of the farnesylated species of prelamin A (reviewed by Young et al 11 ) . In addition, the replacement of a lamin A/C-encoding allele by a lamin C-only allele 13 or a lamin A/C-knockout allele 12 in Zmpste24-deficient mice, or the treatment with FTI of mice with LMNA-linked progeria, 17, 18 both reduce the cellular amount of farnesylated prelamin A and significantly improve the progeroid syndrome. The retention of a farnesylated C terminus is thought to act in a dominant-negative way by becoming permanently anchored to the nuclear membrane, thereby impairing physiological lamin A oligomerization and resulting in cellular ageing. 11 In fibroblasts with LMNA mutations or treated with PIs, the reversion of p16 INK4a overexpression and SA-b-galactosidase activity by inhibition of farnesylation is a strong argument in favor of the pathophysiological role of accumulated farnesylated prelamin A in premature senescence.
The free-radical theory of ageing links ROS hyperproduction with mitochondrial dysfunction, most toxic ROS being byproducts of mitochondrial oxidative phosphorylation and activation of cellular stress pathways. 23, 26 We observed that ROS production was markedly enhanced in fibroblasts with LMNA mutations or treated with PIs. This state of oxidative stress was associated with alterations in the expression of respiratory chain proteins and with a decrease of mitochondrial membrane potential in PI-treated fibroblasts. These defects, together with the colocalization of ROS and mitochondria, are in favor of the mitochondrial origin of the excess ROS in these cells. A vicious circle involving ROS production might reinforce the mitochondrial defects and promote the accumulation of lipid and protein peroxidation products. 37 ROS accumulation can also result from and activate cellular stress pathways that participate in cell growth arrest. 23 Furthermore, ROS can trigger DNA damage, and a defective DNA repair response has been shown to be an important pathophysiological mechanism in premature ageing linked to genetically altered prelamin A maturation. 38 Interestingly, our results using inhibitors of farnesylation argue for a role of farnesylated prelamin A in the increase of cellular ROS. Further studies exploring the precise mechanisms that link farnesylated prelamin A and ROS production are needed.
Mitochondrial alterations and ROS hyperproduction have not previously been described in cells bearing LMNA mutations. In addition, the findings that some PIs induce mitochondrial dysfunction are novel, such alterations being generally attributed to nucleoside reverse transcriptase inhibitors (mainly thymidine analogs). 39, 40 In the treatment of HIV infection, both drugs are commonly associated, which could cause major mitochondrial alterations. Whether PIs or LMNA mutations can induce direct effects on isolated mitochondria needs further investigations.
In conclusion, we show here that both lipodystrophyassociated mutations in A-type lamins and indinavir and nelfinavir treatment favor the retention of cellular farnesylated prelamin A, which trigger oxidative stress and premature senescence. We propose that, in addition to their similar clinical and biological features, lipodystrophic syndromes resulting from LMNA mutations or HIV antiretroviral treatment share common pathophysiological mechanisms leading to premature ageing complications.
Materials and Methods
Patients, cells and tissues. Six female patients with insulin resistance and/ or diabetes associated with abnormal body fat distribution, with lipoatrophy or android habitus, were referred to our laboratory for LMNA genetic testing. They were found to harbor the R482W mutation associated with familial partial lipodystrophy of the Dunnigan type (patient P6) 33 or previously undescribed heterozygous LMNA substitutions (D47Y, L92F, L387V, R399H, L421P). Only the patient with the LMNA D47Y mutation exhibited clinical signs of premature ageing. The precise clinical phenotype of these patients will be presented elsewhere. Primary skin fibroblast cultures were established after punch biopsy at ages 9, 47, 60, 53, 56 and 51 years, respectively. Fibroblasts from two non-obese nondiabetic women aged 20 and 33 years undergoing plastic surgery were used as controls.
We also used subcutaneous abdominal adipose tissue samples from four HIVinfected lipoatrophic patients aged 39-53 years who were on antiretroviral regimens, including indinavir or nelfinavir, and from four HIV-seronegative, nondiabetic, 40-to 60-year-old controls, as described elsewhere. 41 We have previously observed an altered morphology and mitochondrial dysfunction in fat tissue from these HIV-infected patients. 41, 42 Subcutaneous cervical adipose tissue from two lipodystrophic women aged 22 and 33 years and bearing the R482W and R439C LMNA mutations, respectively, was collected during plastic surgery. They were compared to subcutaneous abdominal adipose tissue surgical samples from two nondiabetic non-obese control women aged 20 and 42 years. All the subjects gave their written informed consent for these studies.
Cell culture and treatment. Fibroblasts were grown in DMEM medium (Gibco s Cell Culture, Invitrogen Corporation, San Diego, CA, USA) containing 1 g/l glucose, 20 mM L-glutamine, 25 mM Hepes, 110 mg/ml sodium pyruvate, 10% FBS (PAA Laboratories, Les Mureaux, France), 100 U/ml penicillin and 0.1 mg/ml streptomycin (Invitrogen Corporation) at 371C in 5% CO 2 /95% air. Control fibroblasts were treated or not treated with PIs at Cmax concentrations (indinavir 10 mM, nelfinavir 5 mM or atazanavir 4 mM) 19,43 from passages 2-16. Indinavir was provided by Merck Sharp & Dohme Laboratories (Clermond-Ferrand, France) and nelfinavir by Agouron Pharmaceuticals (San Diego, CA, USA). Atazanavir was kindly provided by Dr. Stéphane Azoulay (CNRS UMR 6001, Nice, France). Control fibroblasts or those with LMNA mutations or treated with PIs were incubated or not with the farnesylation inhibitors FTI-277 (Calbiochem, Darmstadt, Germany) (20 mM for 48 h) or mevinolin (Sigma-Aldrich, Saint Louis, MO, USA) (25 mM for 18 h). In all experiments, fibroblasts with LMNA mutations or treated with PIs were compared to control cells cultured in parallel. Stock solutions of PIs and FTI-277 were prepared in dimethyl sulfoxide (DMSO). In PI-treated cells, the final concentrations of DMSO were p0.005%, below the threshold of toxicity. 19 Nevertheless, DMSO controls were performed on fibroblasts at passages 9-12, previously treated for 7 weeks or more by the solvent at 0.01% in each experiment. In FTI-treated cells, the final concentration of DMSO was 0.1%. The effect of this concentration of solvent has been assessed in parallel on ROS production and SA-b-galactosidase activity.
Cell morphology and immunofluorescence microscopy. Fibroblasts grown on glass coverslips were fixed in cold methanol for 10 min at À201C.
Antibodies directed against lamin A/C (MAB-3211, Chemicon International Inc., Temecula, CA, USA), lamin B (a generous gift from B. Buendia, UPMC, France) and prelamin A (SC-6214, Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) were revealed by using secondary antibodies coupled to Texas Red (Jackson ImmunoResearch Laboratories, West Grove, PA, USA) or fluorescein isothiocyanate (Santa Cruz Biotechnology). Cell nuclei were visualized after diamidino-2phenylindole hydrochloride (DAPI) staining. For each condition, 130-200 control, PI-treated and LMNA-mutated cells were examined.
Western blot analysis. Cell extracts prepared as described previously 21 were subjected to SDS-PAGE, blotted onto nitrocellulose membranes and probed with antibodies against lamin A/C (MAB-3211) or prelamin A (SC-6214, specific for prelamin A, and SC-7292, that recognizes both lamin A/C and prelamin A 31 ). Antibodies against p16 Cell apoptosis. Apoptosis was measured by means of flow cytometry and in terms of the cleavage of the death substrate PARP, as described previously. 40 The percentage of apoptotic cells with subdiploid DNA staining, located in the 'sub-G0/ G1' peak, was measured. Positive control of apoptosis was obtained by treating starved fibroblasts with staurosporine (Sigma-Aldrich) 500 nM for 20 h. Caspase-3-mediated PARP cleavage was estimated by Western blotting whole-cell lysates with an antibody (SC-7150, Santa Cruz Biotechnology) that recognizes the entire (116 000 Da) and cleaved (85 000 Da) forms of PARP.
SA-b-galactosidase assay. b-galactosidase activity at pH 6 has been widely used as a biomarker of cellular senescence in vivo and in vitro. 29 Cells on coverslips were fixed for 3-5 min at 221C with 2% formaldehyde/0.2% glutaraldehyde and incubated overnight at 371C in 1 mg/ml X-gal, 40 mM citric acid-sodium phosphate (pH 6 or 4), 5 mM potassium ferricyanide, 5 mM potassium ferrocyanide, 150 mM NaCl and 2 mM MgCl 2 . The blue-stained cells observed at pH 6 and pH 4 were counted in eight fields at Â 20 magnification (500 cells) and the ratio of pH 6-to pH 4-positive blue cells, which specifically represents SA-bgalactosidase activity, was calculated. Alternatively, blue X-gal cellular staining at pH 6 and pH 4, dissolved in DMSO, was quantified at 630 nm.
ROS production and mitochondrial markers. We used the CM-H 2 DCFDA derivatives (5-(and 6)-chloromethyl-2 0 ,7 0 -dichlorodihydrofluorescein diacetate, acetyl ester, C6827, Molecular Probes) as cell-permeant indicators of ROS, the MitoTracker Red 580 probe (MTR, M-22425; Molecular Probes) as a marker of mitochondria and the cationic dye JC-1 (T-3168, Molecular Probes) as an indicator of mitochondrial membrane potential. 40 Cells were cultured in 96-well plates, then washed and incubated with CM-H 2 DCFDA (9 mM), JC-1 (4 mg/ml), MTR (50 nM) or Hoechst 33258 (0.01 mg/ml) in DMEM medium without FBS for 20 min at 371C in the dark. Quantification was performed with a plate fluorescence reader (Spectrafluor Plus, Tecan-France, Trappes, France) at 520 nm (CM-H 2 DCFDA), 595 and 530 nm (JC-1 aggregates and monomers, respectively), 630 nm (MTR) and 460 nm (Hoechst 33258), respectively. ROS production was also detected by measuring the reduction of NBT (Sigma-Aldrich). Cells were incubated for 90 min in medium containing 0.2% NBT. Dark-blue reduced NBT, dissolved in DMSO, was assessed at 560 nm. CM-H 2 DCFDA (20 mM) and MTR (500 nM) in situ labeling was examined by fluorescence microscopy.
Statistical analysis. All experiments were performed at least three times on triplicate samples. All quantitative results were expressed as means7S.E.M. Comparisons between treated or mutated cells and control cells were made with Student's t-test. P-values o0.05 were considered significant.
